EYE vs NBIX · rev $437.3M vs P/E 45, rev $2.36B
National Vision Holdings Inc (EYE) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
National Vision Holdings Inc (EYE) is a specialty retail company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported EYE revenue for 2024-12-28 was $437.3M. Net income was -$28.6M. Revenue was down 3.2% from 2024-09-28 to 2024-12-28. EYE currently screens at market cap $1.93B.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
EYE currently screens at market cap $1.93B. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the EYE and NBIX stock pages for the full models.
Not investment advice.